WebDisclosure WebDisclosure
Basculer en Français
11251 Companies
249893 Keywords
178205 Articles
135758 Press releases
Headlines Articles Press releases POP Biotechnologies, Inc. Remove
  1. Home
  2. Companies
  3. POP Biotechnologies, Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 09/27/2024 at 20:05, 2 years 1 month ago

    POP Biotechnologies Announces Positive Interim Results for COVID-19 Vaccine Trial

    COVID-19 Vaccine Phase 3 Trial Immunogenicity EuCorVac-19 POP BIO SNAP
  • BRIEF

    published on 09/27/2024 at 20:05, 2 years 1 month ago

    POP Biotechnologies annonce des résultats intermédiaires positifs pour l'essai d'un vaccin contre la COVID-19

    Vaccin Contre Le Covid-19 Essai De Phase 3 EuCorVac-19 POP BIOGRAPHIE INSTANTANÉE Immunogénicité
  • PRESS RELEASE

    published on 09/27/2024 at 20:00, 2 years 1 month ago

    POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

    POP Biotechnologies and EuBiologics announce positive findings of ECV-19 COVID-19 vaccine in Phase 3 trial in the Philippines, demonstrating safety, immunogenicity, and potential against Omicron variant
    COVID-19 Vaccine Phase 3 Trial POP Biotechnologies EuBiologics ECV-19
    Logo of POP Biotechnologies, Inc.
  • PRESS RELEASE

    published on 07/14/2023 at 18:00, 3 years 3 months ago

    POP Biotechnologies and EuBiologics' EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial

    Logo of POP Biotechnologies, Inc.
Accesswire
  • Published on 10/30/2026 at 23:35, 2 days 3 hours ago

    Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement

  • Published on 10/30/2026 at 23:30, 2 days 3 hours ago

    Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario

  • Published on 10/30/2026 at 20:47, 2 days 5 hours ago

    CoTec Holdings Corp. Comments on Share Trading

  • Published on 10/30/2026 at 19:00, 2 days 7 hours ago

    Electric Royalties Ltd. Announces Application for Warrant Extension

  • Published on 10/30/2026 at 15:30, 2 days 11 hours ago

    Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE
EQS Group
  • Published on 11/01/2026 at 10:35, 16 hours 8 minutes ago

    Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video

  • Published on 11/01/2026 at 05:00, 21 hours 43 minutes ago

    2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu

  • Published on 10/31/2026 at 16:35, 1 day 10 hours ago

    SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand

  • Published on 10/30/2026 at 22:49, 2 days 3 hours ago

    EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

  • Published on 10/30/2026 at 22:30, 2 days 4 hours ago

    /C O R R E C T I O N - OCI Global/

View all EQS
Les Echos
  • Published on 10/30/2026 at 23:00, 2 days 3 hours ago

    BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY

  • Published on 10/30/2026 at 23:00, 2 days 3 hours ago

    Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie

  • Published on 10/30/2026 at 20:42, 2 days 6 hours ago

    TINC en PMV investeren in Storm Group (B)

  • Published on 10/30/2026 at 20:42, 2 days 6 hours ago

    TINC and PMV invest in Storm Group (B)

  • Published on 10/30/2026 at 20:42, 2 days 6 hours ago

    TINC and PMV invest in Storm Group (B)

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy